By otakuyassine3@gmail.com 
Senseonics Holdings, Inc. (NYSE:SENS – Get Free Report) rose 9.4% during mid-day trading on Friday . The company traded as high as $0.99 and last traded at $1.00. Approximately 1,630,240 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 17,239,750 shares. The stock had previously closed at $0.92.
Analyst Ratings Changes
SENS has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th. StockNews.com started coverage on shares of Senseonics in a research report on Thursday, December 26th. They issued a “sell” rating on the stock.
Check Out Our Latest Report on Senseonics
Senseonics Price Performance
The stock’s 50-day moving average is $0.62 and its 200-day moving average is $0.46. The firm has a market cap of $598.31 million, a P/E ratio of -7.73 and a beta of 0.69. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.
Senseonics (NYSE:SENS – Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Senseonics had a negative return on equity of 842.25% and a negative net margin of 362.30%. The company had revenue of $4.26 million for the quarter, compared to the consensus estimate of $4.02 million. As a group, equities analysts anticipate that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.
Insider Buying and Selling at Senseonics
In related news, CFO Frederick T. Sullivan purchased 124,933 shares of Senseonics stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the transaction, the chief financial officer now directly owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Timothy T. Goodnow bought 315,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average price of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the transaction, the chief executive officer now owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.
Institutional Trading of Senseonics
A number of institutional investors and hedge funds have recently modified their holdings of SENS. Raymond James Financial Inc. bought a new stake in Senseonics during the 4th quarter worth approximately $26,000. Charles Schwab Investment Management Inc. boosted its position in Senseonics by 9.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company’s stock worth $1,748,000 after acquiring an additional 274,842 shares during the last quarter. Ridgecrest Wealth Partners LLC acquired a new position in Senseonics during the 4th quarter worth approximately $60,000. Geode Capital Management LLC boosted its position in Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock worth $2,042,000 after acquiring an additional 179,103 shares during the last quarter. Finally, FMR LLC boosted its position in Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock worth $59,000 after acquiring an additional 167,970 shares during the last quarter. 12.36% of the stock is owned by institutional investors.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company’s products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.
Featured Articles
Receive News & Ratings for Senseonics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Senseonics and related companies with MarketBeat.com’s FREE daily email newsletter.